Evidence map›Paper›PMID 29246963›Full record

Trial reportJournal of the American Heart Association2017

Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation and Ischemic Stroke: The ARIC (Atherosclerosis Risk in Communities) Study.

Konstantinos N Aronis, Di Zhao, Ron C Hoogeveen, Alvaro Alonso, Christie M Ballantyne, Eliseo Guallar, Steven R Jones, Seth S Martin, Saman Nazarian, Brian T Steffen and 2 more

Open access · goldAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Heart Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 2 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 82 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. The Emerging Lipid Risk: Lipoprotein(a).Korean circulation journal · 2026
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Konstantinos N AronisDivision of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD.
Di ZhaoDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Ron C HoogeveenDivision of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX.
Alvaro AlonsoDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA.
Christie M BallantyneDivision of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX.
Eliseo GuallarDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Steven R JonesDivision of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD.
Seth S MartinDivision of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD.
Saman NazarianDivision of Cardiology, University of Pennsylvania Medical System University of Pennsylvania School of Medicine, Philadelphia, PA.
Brian T SteffenDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN.
Salim S ViraniMichael E. DeBakey Veterans Affairs Medical Center and Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, TX.
Erin D MichosDivision of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD edonnell@jhmi.edu.
Johns Hopkins University · USBaylor College of Medicine · USJohns Hopkins Medicine · USEmory University · USUniversity of Minnesota · USUniversity of Pennsylvania Health System · US

Funding

American Heart Association-American Stroke Association 16EIA26410001
6 · The paper itself

Abstract

backgroundLipoprotein(a) (Lp[a]) is proatherosclerotic and prothrombotic, causally related to coronary disease, and associated with other cardiovascular diseases. The association of Lp(a) with incident atrial fibrillation (AF) and with ischemic stroke among individuals with AF remains to be elucidated. METHODS AND

resultsIn the community-based ARIC (Atherosclerosis Risk in Communities) study cohort, Lp(a) levels were measured by a Denka Seiken assay at visit 4 (1996-1998). We used multivariable-adjusted Cox models to compare AF and ischemic stroke risk across Lp(a) levels. First, we evaluated incident AF in 9908 participants free of AF at baseline. AF was ascertained by electrocardiography at study visits, hospital

conclusionsHigh Lp(a) levels were not associated with incident AF. Lp(a) levels were associated with increased ischemic stroke risk, primarily among individuals without AF but not in those with AF.

Indexed as

Risk AssessmentAtherosclerosisAtrial FibrillationBiomarkersBrain IschemiaCoronary Artery DiseaseElectrocardiographyFemaleFollow-Up StudiesHumansIncidenceLipoprotein(a)MaleMiddle AgedProspective StudiesRisk FactorsBiomarkersLipoprotein(a)atrial fibrillationcardioembolic strokeepidemiologylipoproteinlipoprotein (a)risk factorstroke

Identifiers

PMID29246963
PMCPMC5779047
OpenAlexW2772979387

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.